exact sciences corp. - EXAS
EXAS
Close Chg Chg %
43.45 1.11 2.55%
Closed Market
44.56
+1.11 (2.55%)
Volume: 1.68M
Last Updated:
Apr 2, 2025, 4:00 PM EDT
Company Overview: exact sciences corp. - EXAS
EXAS Key Data
| Open $42.85 | Day Range 42.54 - 45.16 |
| 52 Week Range 40.62 - 74.44 | Market Cap $8.07B |
| Shares Outstanding 185.76M | Public Float 182.95M |
| Beta 1.14 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$5.56 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.02M |
EXAS Performance
| 1 Week | 2.06% | ||
| 1 Month | -6.01% | ||
| 3 Months | -22.17% | ||
| 1 Year | -36.55% | ||
| 5 Years | -20.07% |
EXAS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
29
Full Ratings ➔
About exact sciences corp. - EXAS
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
EXAS At a Glance
EXACT Sciences Corp.
5505 Endeavor Lane
Madison, Wisconsin 53719
| Phone | 1-608-284-5700 | Revenue | 2.76B | |
| Industry | Medical Specialties | Net Income | -1,028,857,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 10.365% | |
| Fiscal Year-end | 12 / 2025 | Employees | 7,000 | |
| View SEC Filings |
EXAS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.752 |
| Price to Book Ratio | 4.342 |
| Price to Cash Flow Ratio | 49.16 |
| Enterprise Value to EBITDA | 523.937 |
| Enterprise Value to Sales | 4.381 |
| Total Debt to Enterprise Value | 0.23 |
EXAS Efficiency
| Revenue/Employee | 394,123.857 |
| Income Per Employee | -146,979.571 |
| Receivables Turnover | 10.897 |
| Total Asset Turnover | 0.421 |
EXAS Liquidity
| Current Ratio | 2.146 |
| Quick Ratio | 1.924 |
| Cash Ratio | 1.418 |
EXAS Profitability
| Gross Margin | 69.547 |
| Operating Margin | -6.952 |
| Pretax Margin | -37.557 |
| Net Margin | -37.293 |
| Return on Assets | -15.716 |
| Return on Equity | -37.092 |
| Return on Total Capital | -19.87 |
| Return on Invested Capital | -19.557 |
EXAS Capital Structure
| Total Debt to Total Equity | 115.548 |
| Total Debt to Total Capital | 53.607 |
| Total Debt to Total Assets | 44.974 |
| Long-Term Debt to Equity | 103.711 |
| Long-Term Debt to Total Capital | 48.115 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Exact Sciences Corp. - EXAS
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.77B | 2.08B | 2.50B | 2.76B | |
Sales Growth
| +18.49% | +17.95% | +19.93% | +10.37% | |
Cost of Goods Sold (COGS) incl D&A
| 553.76M | 671.84M | 746.41M | 840.15M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 206.17M | 226.20M | 234.50M | 214.86M | |
Depreciation
| 111.17M | 128.75M | 142.34M | 119.70M | |
Amortization of Intangibles
| 95.00M | 97.45M | 92.16M | 95.16M | |
COGS Growth
| +23.68% | +21.32% | +11.10% | +12.56% | |
Gross Income
| 1.21B | 1.41B | 1.75B | 1.92B | |
Gross Income Growth
| +16.26% | +16.41% | +24.14% | +9.43% | |
Gross Profit Margin
| +68.66% | +67.77% | +70.14% | +69.55% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.94B | 2.03B | 2.06B | 2.11B | |
Research & Development
| 300.35M | 393.42M | 425.88M | 431.21M | |
Other SG&A
| 1.64B | 1.64B | 1.64B | 1.68B | |
SGA Growth
| +63.50% | +4.67% | +1.52% | +2.24% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 95.97M | (40.65M) | (7.10M) | 846.61M | |
EBIT after Unusual Expense
| (825.18M) | (580.27M) | (303.76M) | (1.04B) | |
Non Operating Income/Expense
| 1.28M | (32.67M) | 111.14M | 34.81M | |
Non-Operating Interest Income
| - | - | - | 1.79M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 18.61M | 19.63M | 9.12M | 32.57M | |
Interest Expense Growth
| -78.86% | +5.53% | -53.53% | +256.99% | |
Gross Interest Expense
| 18.61M | 19.63M | 9.12M | 32.57M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (842.51M) | (632.57M) | (201.75M) | (1.04B) | |
Pretax Income Growth
| +1.70% | +24.92% | +68.11% | -413.60% | |
Pretax Margin
| -47.68% | -30.35% | -8.07% | -37.56% | |
Income Tax
| (246.88M) | (9.06M) | 2.40M | (7.30M) | |
Income Tax - Current - Domestic
| 1.39M | 2.17M | 2.27M | 933.00K | |
Income Tax - Current - Foreign
| 4.90M | 1.13M | 2.56M | 1.88M | |
Income Tax - Deferred - Domestic
| (253.22M) | (12.22M) | 566.00K | (9.92M) | |
Income Tax - Deferred - Foreign
| 54.00K | (147.00K) | (2.99M) | (199.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (595.63M) | (623.51M) | (204.15M) | (1.03B) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (595.63M) | (623.51M) | (204.15M) | (1.03B) | |
Net Income Growth
| +29.81% | -4.68% | +67.26% | -403.97% | |
Net Margin Growth
| -33.71% | -29.91% | -8.17% | -37.29% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (595.63M) | (623.51M) | (204.15M) | (1.03B) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (595.63M) | (623.51M) | (204.15M) | (1.03B) | |
EPS (Basic)
| -3.4761 | -3.5356 | -1.1332 | -5.5856 | |
EPS (Basic) Growth
| +38.08% | -1.71% | +67.95% | -392.91% | |
Basic Shares Outstanding
| 171.35M | 176.35M | 180.14M | 184.20M | |
EPS (Diluted)
| -3.4761 | -3.5356 | -1.1332 | -5.5856 | |
EPS (Diluted) Growth
| +38.08% | -1.71% | +67.95% | -392.91% | |
Diluted Shares Outstanding
| 171.35M | 176.35M | 180.14M | 184.20M | |
EBITDA
| (523.04M) | (394.72M) | (76.36M) | 23.07M | |
EBITDA Growth
| -1,608.88% | +24.53% | +80.65% | +130.21% | |
EBITDA Margin
| -29.60% | -18.94% | -3.05% | +0.84% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 69.391 | |
| Number of Ratings | 29 | Current Quarters Estimate | -0.082 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -0.34 | |
| Last Quarter’s Earnings | -0.315 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -5.59 | Next Fiscal Year Estimate | 0.605 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 20 | 20 | 22 | 22 |
| Mean Estimate | -0.08 | 0.02 | -0.34 | 0.61 |
| High Estimates | 0.23 | 0.27 | 1.02 | 2.78 |
| Low Estimate | -0.59 | -0.48 | -2.19 | -0.37 |
| Coefficient of Variance | -198.30 | 939.68 | -186.54 | 114.00 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 20 | 20 | 18 |
| OVERWEIGHT | 6 | 6 | 5 |
| HOLD | 3 | 3 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Exact Sciences Corp. - EXAS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Exact Sciences Corp. - EXAS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 11, 2025 | Kevin T. Conroy President and CEO; Director | 1,203,269 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $22.38 per share | 26,929,160.22 |
| Mar 11, 2025 | Kevin T. Conroy President and CEO; Director | 1,154,340 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $47.06 per share | 54,323,240.40 |
| Mar 11, 2025 | Kevin T. Conroy President and CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Brian Baranick EVP, GM, Precision Oncology | 3,955 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | James M. Herriott SVP, General Counsel & Sec | 13,893 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Jake Orville EVP, GM, Screening | 20,277 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.28 per share | 1,039,804.56 |
| Feb 27, 2025 | Jake Orville EVP, GM, Screening | 22,136 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Jake Orville EVP, GM, Screening | 28,779 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Jake Orville EVP, GM, Screening | 3,955 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | James M. Herriott SVP, General Counsel & Sec | 13,738 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Sarah Condella EVP, Human Resources | 80,297 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Sarah Condella EVP, Human Resources | 78,438 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.28 per share | 4,022,300.64 |
| Feb 27, 2025 | Sarah Condella EVP, Human Resources | 23,817 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Sarah Condella EVP, Human Resources | 3,955 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Brian Baranick EVP, GM, Precision Oncology | 19,841 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | James M. Herriott SVP, General Counsel & Sec | 12,963 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.28 per share | 664,742.64 |
| Feb 27, 2025 | Kevin T. Conroy President and CEO; Director | 13,181 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | James M. Herriott SVP, General Counsel & Sec | 1,648 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Brian Baranick EVP, GM, Precision Oncology | 28,779 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Aaron Bloomer EVP, Chief Financial Officer | 28,779 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |